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Abstract 
A group of patients with pneumonia caused by severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) were reported from China in December 2019. Although several antiviral drugs 
are widely tested, none of them has been approved as specific antiviral therapy for coronavirus 
disease 2019 (COVID-19). Accumulating evidence established a hyperinflammatory states or 
cytokine storm in COVID-19. Among these cytokines, IL-6 plays a key role in cytokine storm 
and can predict the adverse clinical outcomes and fatality in these patients. 
Based on the evidence of the significant role of IL-6 in cytokine storm, diabetes mellitus and 
cardiovascular diseases as principal comorbidities, it seems that anti-cytokine therapy may be 
useful in patients with severe COVID-19 to reduce mortality. Recent studies demonstrated that 
herbal-derived natural products had immunosuppressive and anti-inflammatory properties and 
exhibited exceptional act on mediators of inflammation. Parthenolide is the principal 
sesquiterpene lactones and the main biologically active constituent Tanacetum parthenium 
(commonly known as feverfew) which has could significantly reduce IL-1, IL-2, IL-6, IL-8, and 
TNF-α production pathways established in several human cell line models in vitro and in vivo 
studies. Therefore, parthenolide may be one of the herbal candidates for clinical evaluation. 
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Dear Editor, 
A group of patients with pneumonia caused by severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) were reported from China in December 2019 (Tu et al. 2020; Clerkin et al., 
2020; Guo et al., 2020). It rapidly spread throughout the world and led to a fatal pandemic 
(Clerkin et al., 2020; Cao, 2020). Up to now, although several antiviral drugs are widely tested, 
none of them has been approved as specific antiviral therapy for coronavirus disease 2019 
(COVID-19), and the mainstay of treatment is based on the management of patient's symptoms 
(Tu et al. 2020; Cao, 2020). Therefore, vaccines, monoclonal antibodies (mAbs), and novel 
therapies are of interest worldwide (Tu et al. 2020; Clerkin et al., 2020; Cao, 2020). 
Accumulating evidence established a hyperinflammatory states or cytokine storm in COVID-19. 
Elevated levels of inflammatory cytokines, including interleukin-2 (IL-2), IL-6, IL-8, IL-17, IL-
1β, and tumor necrosis factor-alpha (TNF-α), which damage the heart, liver, and kidneys may 
play a significant role in the pathogenesis of COVID-19, leading to shock as well as respiratory 
and multiorgan failure (Guo et al., 2020; Cao, 2020; Zhang et al., 2020). Among these cytokines, 
IL-6 plays a key role in cytokine storm and can predict the adverse clinical outcomes and fatality 
in these patients (Tu et al., 2020; Guo et al., 2020; Zhang et al., 2020). Interleukin-6 is a tow-
faced cytokine and considered a pro-inflammatory and anti-inflammatory cytokine, which is 
produced by immune cells. Its serum levels in the healthy state prepare immune responses of the 
host and sustained overproduction of IL-6 is involved in a number of inflammatory diseases (Tue 
et al., 2020; Cao, 2020; Zhang et al., 2020). A high level of IL-6, which is detected in patients 
with severe and complicated COVID-19, has a relationship with decreased lung elasticity and 
more severe bronchoalveolar inflammation. Furthermore, elevated levels of circulating IL-6 
significantly correlated with the need for mechanical ventilation and poor outcome in patients 
with severe COVID-19 which were complicated by pneumonia and acute respiratory distress 
syndrome (ARDS) (Tue et al., 2020; Cao, 2020; Zhang et al., 2020). Interleukin-6 participates in 
the pathogenesis of common comorbidities of COVID-19 e.g., diabetes mellitus (DM) and 
cardiovascular diseases (CVDs) (Gue et al., 2020; Zhang et al., 2020). In addition, considerably 
elevated levels of circulating IL-6 were seen in COVID-19 patients with DM and myocardial 
injury. The data supports the fact that DM is a risk factor for rapid deterioration and poor 
prognosis of COVID-19 (Clerkin et al., 2020; Guo et al., 2020). 
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Based on the evidence of the significant role of IL-6 in cytokine storm, DM, and CVDs, it seems 
that anti-cytokine therapy such as Tocilizumab (Anti-IL-6R) may be useful in patients with 
severe COVID-19 to reduce mortality (Tu et al., 2020; Clerkin et al., 2020; Zhang et al., 2020). 
The use of Tocilizumab in a preliminary investigation has quickly reduced fever and improved 
respiratory function in these patients and there are ongoing clinical trials (Tu et al., 2020; Clerkin 
et al., 2020; Cao, 2020). Recent studies demonstrated that herbal-derived natural products had 
immunosuppressive and anti-inflammatory properties and exhibited exceptional act on mediators 
of inflammation. Curcuma Longa, Glycyrrhiza Species, Camellia Sinensis, Salvia Miltiorrhiza 
and Tanacetum parthenium, have indicated immunomodulatory properties by reducing pro-
inflammatory cytokines and mediators (Amirghofran, 2012). Tanacetum parthenium (commonly 
known as feverfew) prevents releasing of pro-inflammatory mediators from macrophages and 
lymphocytes (Amirghofran, 2012; George et al., 2012). This is a perennial plant, frequently 
grows in various regions of the world. The history of medical application of feverfew backs to 
ancient Greek, Dioscorides prescribed this plant for reducing fever and “all hot inflammations”. 
Therefore, it was called the “medieval aspirin” (Pareek et al., 2011). Feverfew has been used in 
traditional and folk medicine for the treatment of fever, cold, asthma, migraine headache, 
arthritis, women's health issues, inflammatory conditions, etc. (George et al., 2012; Pareek et al., 
2011). Although the qualitative standard of many trials in the phytopharmacological field are less 
rigorous than the conventional pharmaceutical sector (Williamson et al., 2020), clinical evidence 
suggests that feverfew extract might have positive results in migraine prevention (Lopresti et al., 
2020). Phytochemical studies have shown the presence of many active ingredients of feverfew, 
including sesquiterpene lactones, flavonoid glycosides, sesquiterpenes, and monoterpenes. 
Parthenolide is the principal sesquiterpene lactones and the main biologically active constituent 
in this plant (Pareek et al., 2011), which has different pharmacological properties, including 
antioxidant, anti-inflammatory, analgesic, antimicrobial, anti-migraine, and anticancer activities 
(George et al., 2012; Wang et al., 2015). Moreover, parthenolide has been shown potent 
inhibitory effects on pro-inflammatory pathways such as NF-kB and LPS pathways. 
Interestingly, parthenolide could significantly reduce IL-1, IL-2, IL-6, IL-8, and TNF-α 
production pathways established in several human cell line models in vitro (monocytes, 
macrophages, neutrophils) and in vivo studies (Wang et al., 2015; Magni et al., 2012). Although 
specific blockade of pro-inflammatory cytokines using mAbs is one of the main therapeutic 
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strategies for the management of cytokine storm in COVID19, parthenolide may be one of the 
herbal candidates for clinical evaluation.  
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